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Cardiovascular and Cancer Mortality in Very
Elderly Post-Myocardial Infarction Patients
Receiving Statin Treatment
Klas Gränsbo, MD,* Olle Melander, MD,* Lars Wallentin, MD,† Johan Lindbäck, PHD,†
Ulf Stenestrand, MD,‡ Jörg Carlsson, MD,§ Jan Nilsson, MD*
Malmö, Lund, Uppsala, Linköping, and Kalmar, Sweden
Objectives The purpose of this study was to determine whether statin treatment is effective and safe in very elderly
(80 years and older) acute myocardial infarction (AMI) patients.
Background Elderly individuals constitute an increasing percentage of patients admitted to hospitals for AMI. Despite that
these patients have a higher mortality risk, the application of evidence-based medicine remains much lower
than for younger patients.
Methods We included all patients 80 years and older who were admitted with the diagnosis of AMI in the Register of In-
formation and Knowledge About Swedish Heart Intensive Care Admissions between 1999 and 2003 (n 
21,410). Of these, complete covariate and follow-up data were available for 14,907 patients (study population A). To
limit the bias related comorbidity on statin therapy, we also performed analyses excluding patients who died
within 14 days of the acute event (study population B) and all patients who died within 365 days (study popula-
tion C). A propensity score was used to adjust for initial differences between treatment groups.
Results All-cause mortality was significantly lower in patients receiving statin treatment at discharge in study population
A (relative risk: 0.55, 95% confidence interval: 0.51 to 0.59), in study population B (relative risk: 0.65; 95% con-
fidence interval: 0.60 to 0.71), and in study population C (relative risk: 0.66; 95% confidence interval: 0.59 to
0.76). Similar observations were made for cardiovascular mortality as well as for AMI mortality. There was no
increase in cancer mortality in statin-treated patients.
Conclusions Statin treatment is associated with lower cardiovascular mortality in very elderly post-infarction patients without
increasing the risk of the development of cancer. (J Am Coll Cardiol 2010;55:1362–9) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.013m
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pith increased life expectancy, the population of older
atients is growing and cardiovascular disease remains the
ajor cause of mortality in this age group. More than 80%
f all coronary deaths occur in patients older than the age of
5 years (1). Despite that elderly patients with acute
oronary syndromes have a higher short- and long-term
ortality risk, the application of evidence-based medicine
emains much lower than for younger patients (2–6). A
arge number of clinical trials have established that treat-
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Manuscript received October 20, 2009; revised manuscript received January 20,
010; accepted January 25, 2010.ent with lipid-lowering statins significantly reduces car-
iovascular mortality in post-myocardial infarction patients
7). However, data from observational studies such as
RACE (Global Registry of Acute Coronary Events) (8)
nd the Euro Heart Survey on ACS (9) suggest that 40%
f myocardial infarction patients older than 75 years are
rescribed statins at discharge. Several circumstances may to
ontribute to a lower use of statins in elderly post-
yocardial infarction patients. The association between
lasma cholesterol and cardiovascular risk diminishes with
ncreasing age (10,11), and most lipid trials have excluded
lder patients. There may also be the fear of more side
ffects when treating older patients. The PROSPER
PROspective Study of Pravastatin in the Elderly at Risk) is
he only randomized, controlled trial that specifically stud-
ed the effect of statin treatment in older (70 to 82 years)
atients (12). In this trial, treatment with 40 mg pravastatin
aily was found to reduce fatal/nonfatal cardiovascular
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March 30, 2010:1362–9 Statin Treatment in Elderly Post-MI Patientsvents by 15% and fatal/nonfatal acute myocardial infarction
AMI) by 19%, but pravastatin treatment was also associ-
ted with a 25% increase in cancer incidence. Although
eta-analyses of all major statin trials have shown no
ncrease in cancer incidence (12), it cannot be excluded that
lder patients are at higher risk in this respect. In the
resent study, we used the Register of Information and
nowledge About Swedish Heart Intensive Care Admis-
ions (RIKS-HIA) to analyze the association of statin
reatment with all-cause mortality, cardiovascular mortality,
nd cancer mortality in a cohort of 14,907 very elderly (80
ears and older) myocardial infarction patients.
ethods
IKS-HIA. RIKS-HIA includes all consecutive patients
dmitted to the coronary care units of all participating
wedish hospitals. Data on approximately 100 different
ariables regarding baseline characteristics, examinations,
nterventions, and complications in hospital and discharge
edication and diagnosis were reported in case records, as
escribed elsewhere (13). The variables in RIKS-HIA
omply with the international Cardiology Audit and Reg-
stration Data Standards). To ensure the validity of the
nformation entered into the database, a single specially
rained monitor visited participating hospitals and com-
ared information in the patient records, including electro-
aseline Characteristics in Study Populations A and CTable 1 Baseline Characteristics in Study Populations A and C
Study Popula
No Statins
(n  11,522)
Age (yrs) 84 (82–87)
Women 51.3 (5,909)
Diabetes 21.2 (2,442)
Hypertension 37.4 (4,304)
Current smoker 6.8 (779)
History of stroke 17.3 (1,990)
History of kidney failure 1.9 (224)
History of COPD 7.6 (876)
History of dementia 0.6 (73)
History of heart failure 25.0 (2,876)
History of MI 26.7 (3,081)
History of peripheral artery disease 7.8 (894)
History of cancer 5.0 (572)
History of PCI/CABG 6.4 (738)
Statins at admission 1.8 (202)
Beta-blockers at admission 39.8 (4,588)
ASA at admission 50.9 (5,870)
ACE inhibitors at admission 20.8 (2,401)
Clopidogrel at admission 1.7 (199)
Beta-blockers at discharge 65.3 (7,521)
ASA at discharge 72.6 (8,363)
ACE inhibitors at discharge 36.7 (4,234)
Clopidogrel at discharge 7.9 (912)
alues median (interquartile range) or % (n).
ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; CABG  coronary artery bypass
ercutaneous coronary intervention.ardiography, with the informa-
ion entered into the RIKS-HIA
atabase in 30 to 40 randomly
hosen patients for each hospital.
ata quality was monitored in
,446 random records from all
articipating hospitals, compris-
ng 299,530 measurements.
here was a 94% overall agree-
ent between the registered in-
ormation and patient records.
etween 1999 and 2001, the number of participating
ospitals increased from 65 to 72, out of all 74 Swedish
ospitals, where it remained through 2003.
All patients for whom data were entered into RIKS-HIA
ere informed of their participation in the registry (patients
ould request to be excluded) and the long-term follow-up.
he registry and the merging with other registries were
pproved by the National Board of Health and Welfare and
he Swedish Data Inspection Board. The Ethics Committee
f Uppsala University Hospital approved the study.
tudy population. We included all patients 80 years of age
nd older who were admitted with the diagnosis of AMI in
he RIKS-HIA between January 1, 1999, and December 31,
003 (n  21,410). To be included in the end point
nalyses, we required complete data on all covariates that
Study Population C
Statins
(n  3,385)
No Statins
(n  4,967)
Statins
(n  1,771)
82 (81–84) 84 (81–86) 82 (80–84)
51.0 (1,727) 51.1 (2,538) 52.1 (923)
21.4 (725) 18.8 (936) 19.2 (340)
44.3 (1,500) 37.0 (1,836) 42.5 (752)
6.3 (213) 6.7 (332) 5.5 (97)
14.4 (489) 13.9 (688) 12.0 (212)
1.7 (56) 1.2 (61) 1.0 (18)
5.4 (184) 6.7 (332) 4.9 (87)
0.1 (5) 0.4 (21) 0.4 (1)
18.7 (632) 19.0 (946) 15.6 (276)
30.1 (1,018) 25.2 (1,253) 28.1 (497)
7.4 (251) 5.6 (278) 5.8 (103)
4.0 (134) 4.2 (208) 3.6 (63)
21.0 (712) 7.6 (378) 19.3 (341)
28.8 (974) 1.3 (65) 25.8 (457)
49.0 (1,657) 38.8 (1,927) 47.2 (836)
54.3 (1,839) 49.8 (2,475) 51.6 (914)
24.4 (826) 18.9 (973) 20.9 (370)
3.8 (127) 1.3 (66) 2.6 (46)
85.3 (2,888) 76.2 (3,787) 85.5 (1,515)
86.2 (2,918) 84.0 (4,174) 87.3 (1,546)
53.2 (1,800) 42.9 (2,129) 51.9 (920)
24.9 (838) 8.3 (414) 18.4 (326)
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
RIKS-HIA  Register of
Information and Knowledge
About Swedish Heart
Intensive Care Admissions
RR  relative risktion Agrafting; COPD  chronic obstructive pulmonary disease; MI  myocardial infarction; PCI 
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Statin Treatment in Elderly Post-MI Patients March 30, 2010:1362–9ere adjusted for and specific cause of death in those who
ied during follow-up, leaving 14,907 patients for survival
nalyses (study population A) (Table 1).
Furthermore, to limit the bias related to effects of short
ife expectancy and comorbidity on physicians’ choice of
reatment, we excluded patients who died within 14 days
rom baseline (study population B) (Online Table 1) and all
atients who died within 365 days (study population C)
Table 1). The study design is summarized in Figure 1.
ardiovascular drug therapies were entered in a structured
ormula on admission and at discharge. We used data from
he Swedish National Patient Register to record a diagnosis
f stroke, kidney failure, chronic obstructive pulmonary
isease, dementia, congestive heart failure, myocardial in-
arction, peripheral artery disease, and cancer before the
egistration in RIKS-HIA.
ollow-up and end points. Patients were followed for end
oints with a median follow-up time of 296 days (inter-
uartile range: 44 to 738 days, maximum of 5 years) by
inking the Swedish 10-digit personal number with the
wedish National Cause of Death Register and the Na-
ional Patient Register from baseline until the time of first
vent, death, or until December 31, 2003. End points were
efined according to the International Classification of
iseases 10th Revision. Mortality end points were retrieved
rom the Swedish National Cause of Death Register with
odes I21-I22 defining AMI mortality, codes I00-I99 de-
Total population
n = 21410
Study population C
n = 6738
Study population A
Complete data
n = 14907
Study population B
n = 12320
Figure 1 Flowchart of Current Study Populations
The target population was composed of patients 80 years and older who were adm
acute myocardial infarction in the Register of Information and Knowledge of Swedining cardiovascular mortality, and codes C00-D48 defin-
ng cancer mortality. In analyses of fatal and nonfatal AMI,
nd points were defined as codes I21-I22 in the National
atient Register or Swedish National Cause of Death
egister. The date of hospital discharge was defined as the
aseline.
tatistical analysis. Apart from exclusion of patients with
hort survival time (i.e., restricting the study population to
tudy populations B and C), we attempted to further
ecrease bias related to comorbidities and the physicians’
robability to prescribe statins at discharge by creating and
djusting for a propensity score.
The propensity score is defined as the conditional prob-
bility to receive treatment given the known baseline char-
cteristics. At best, the propensity score captures all the
nitial differences among the treatment groups in 1 score
hat can be used for adjustments in subsequent analyses. The
ropensity score was estimated using a logistic regression
odel including the baseline variables, including cardiovascular
edications at admission, as presented in Table 1.
We used Cox regression models to establish the relation-
hip between statin treatment at the time of discharge and
ime to event. The models included other cardiovascular
edications at discharge (beta-blockers, acetylsalicylic acid,
ther platelet inhibitors, and angiotensin-converting en-
yme inhibitors), statin treatment on admission, the pro-
ensity score, and year of admission. The results are
Patients excluded because
of death between day 15 and 365
n = 5582
Patients excluded because
of death within 14 days
n = 2587
Patients excluded due to missing
data on covariates or 
specific cause of death 
n = 6503
with the diagnosis of
rt Intensive Care Admissions.itted
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March 30, 2010:1362–9 Statin Treatment in Elderly Post-MI Patientsresented as relative risk (RR) and 95% confidence interval
CI). All statistical analyses were done using R version 2.8.1
R Foundation for Statistical Computing, Vienna, Austria).
esults
f the total number of patients in study population A (n 
4,907), 8,817 (59.1%) patients died during follow-up. Of
hose who died, 6,929 (78.6%) patients died of cardiovas-
ular causes (myocardial infarction, other ischemic heart
iseases, congestive heart failure, stroke, cardiac arrhyth-
ias, and other cardiac causes), 4,423 (50.2%) patients died
f myocardial infarction, and 477 (5.4%) patients died of
ancer. Because a significant proportion of the original study
opulation was excluded due to missing data, we compared
emographic and risk factor variables between those with
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Figure 2 Adjusted Cumulative Risk of All-Cause Mortality Estim
RR  relative risk; trunc  truncation time; trunc  0 days  all patients included
after discharge were excluded from analysis; trunc  365 days  patients who di
ortality Outcome in Elderly Post-MI Patients Discharged With orTable 2 Mortality Outcome in Elderly Post-MI Patients Dischar
Mortality
Study
Population*
Events Time at Risk*
No Statin Statin No Statin S
Total A 7,718 1,099 13.96
B 5,392 926 13.94
C 2,198 374 12.27
CVD A 6,070 859 13.96
B 3,945 702 13.94
C 1,478 244 12.27
AMI A 3,910 513 13.96
B 1,901 375 13.94
C 627 105 12.27
Cancer A 399 78 13.96
B 385 77 13.94
C 203 49 12.27
Study population A refers to entire study population; study population B refers to patients who s
ays after discharge. †Expressed as multiples of 1,000 person-years. ‡Crude RR is calculated as th
egression models were adjusted for cardiovascular medications other than statins at discharg
nhibitors), statin treatment on admission, the propensity score, and year of admission.
AMI  acute myocardial infarction; CVD  cardiovascular disease; LCL  lower 95% confidencomplete data (n  14,907) and those excluded due to
issing data (n  6,503). In general, the patients with
issing data (Online Table 2) had a higher burden of
revalent disease compared with patients with complete
ata (Table 1).
All-cause mortality was markedly lower in patients re-
eiving statin treatment at discharge in study populations A,
, and C (Table 2, Fig. 2). However, the RR for mortality
ssociated with statin treatment was clearly dependent on
hether patients who died early after discharge were ex-
luded (Fig. 3). The RR reduction for mortality in statin-
reated compared with non–statin-treated patients seemed
o be less pronounced in study population B than in study
opulation A, and it decreased even further as we excluded
atients who died during the first 180 days from baseline in
3 4 5
ty, trunc = 14 days
mission (years)
RR: 0.62 (0.57, 0.67)
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No statins 4967 4967 2883 1513 577 1
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at the Mean of Each Covariate Included in the Model
alysis; trunc  14 days  patients who died within 14 days
65 days after discharge were excluded from analysis.
ut Statinsith or Without Statins
Events per
1,000 Patient-Years
Crude RR‡
Cox-Regression§
No Statin Statin RR LCL UCL
552.7 237.3 0.43 0.55 0.51 0.59
386.8 200.1 0.52 0.62 0.57 0.67
179.2 93.8 0.52 0.64 0.57 0.73
434.7 185.5 0.43 0.55 0.51 0.60
283.0 151.7 0.54 0.64 0.58 0.70
120.5 61.2 0.51 0.61 0.52 0.72
280.2 110.8 0.40 0.53 0.48 0.59
136.4 81.0 0.59 0.67 0.59 0.77
51.1 26.3 0.52 0.62 0.49 0.79
28.6 16.9 0.59 0.62 0.47 0.82
27.6 16.6 0.60 0.63 0.47 0.83
16.6 12.3 0.74 0.83 0.59 1.19
at least 14 days after discharge; study population C refers to patients who survived at least 365
of events per 1,000 person-years between the statin and the no statin treatment groups. §All Cox
-blockers, acetylsalicylic acid, other thrombocyte inhibitors, and angiotensin-converting enzyme
al; RR  relative risk; UCL  upper 95% confidence interval.2
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Statin Treatment in Elderly Post-MI Patients March 30, 2010:1362–9stepwise manner. This suggested that part of the statistical
elationship between statin treatment and mortality was
ttributed to bias related to comorbidities and the physi-
ians’ inclination to prescribe statins at discharge. Exclusion
f all patients who died during the first year from baseline
id not seem to further influence RR for mortality in
tatin-treated versus nonstatin-treated patients, suggesting
hat such bias was of less importance in study population C
ompared with study populations A and B (Fig. 3).
We subsequently performed stratified analyses in patients
elonging to different quartiles of the propensity score, in
hose with and without myocardial infarction or congestive
eart failure before admission, and by sex in study popula-
ion C. The lower risk of all-cause mortality in patients
reated with statins compared with those not treated with
tatins was significant in all these subgroups except in the
owest quartile of the propensity score (Table 3).
In study population C, the RR of cardiovascular mortality
s well as AMI mortality was markedly lower in patients
reated with statins compared with patients not treated with
tatins at discharge (Figs. 4 and 5). Results were similar in
tudy populations A and B (Table 2). The RR for the
ombination of fatal and nonfatal AMI during follow-up
as reduced to a somewhat lesser degree compared with the
R for AMI mortality in study population C (RR: 0.69;
5% CI: 0.56 to 0.84), study population B (RR: 0.84; 95%
I: 0.76 to 0.92), and study population A (RR: 0.70; 95%
I: 0.65 to 0.76).
There was no increase in cancer mortality in statin-
reated compared with non–statin-treated patients regard-
ess of whether patients who died at different times during
Truncation time (days)
R
R
0.
50
0.
55
0.
60
0.
70
0.
80
0 30 90 180 365
Figure 3 RR of Mortality After Stepwise Exclusion
of Patients Who Died Early After Discharge
Relative risk (RR) (with 95% confidence intervals as vertical bars) of all-cause
mortality for patients discharged with statins after truncation of the study popu-
lation at 0, 7, 14, 30, 60, 90, 180, and 365 days after discharge. Only
patients who survived at least as long as the respective truncation time are
included in the analysis. Adjustments were done using the propensity score.he first year from baseline were excluded, and it was even aower in statin-treated patients in study populations B and
(Table 2). The RR for cancer mortality was similar in
tatin-treated and nonstatin-treated patients in study pop-
lation C (Table 2, Fig. 6).
iscussion
his large observational study with complete long-term
ollow-up for up to 5 years (median 296 days) provides
trong evidence of an association between statin treatment
n very elderly (80 years of age and older) post-myocardial
nfarction patients and reduced cardiovascular mortality.
tatin treatment at hospital discharge after AMI was
ssociated with a reduction of all-cause mortality by 42% in
he entire study cohort and by 34% if the analysis was
estricted to patients who survived at least 1 year after the
vent. A total of 9,576 patients died during follow-up and
6.3% of these died of cardiovascular disease. Statin treat-
ent was associated with a reduction of cardiovascular
ortality by 41% and AMI mortality by 44% in the entire
ohort and by 37% and 37%, respectively, in the cohort of
atients surviving at least 1 year. Collectively, these obser-
ations suggest that the protective effect of statin treatment
n very elderly patients post-myocardial infarction is of a
imilar relative magnitude as that demonstrated in random-
zed clinical trial for middle-age subjects (7) and that it may
n absolute terms be even greater. Although the present
tudy did not include patients younger than 80 years of age,
t is of interest to note that a previous study of RIKS-HIA
atients younger than 80 years of age revealed a 25%
eduction of mortality in subjects prescribed a statin at
ischarge (13).
Patients discharged on statin treatment were more likely
o have been taking statins at hospital admission (Table 1).
t has been reported that pre-treatment with statins is
ssociated with smaller myocardial infarction size (14,15),
elative Risk of All-Cause Mortalityor Diff rent Subgroups in Population C*Table 3 Relative Ri k of All-Cause Mortalityfor Different Subgroups in Population C*
Variable RR LCL UCL
History of heart failure
No 0.65 0.56 0.77
Yes 0.60 0.46 0.78
History of AMI
No 0.63 0.53 0.74
Yes 0.66 0.53 0.82
Sex
Male 0.61 0.51 0.73
Female 0.69 0.57 0.82
Propensity group
Q1 0.93 0.67 1.29
Q2 0.61 0.46 0.79
Q3 0.55 0.44 0.70
Q4 0.70 0.55 0.89
Study population C refers to patients who survived at least 365 days after discharge.
Q1  first quartile; Q2  second quartile; Q3  third quartile; Q4  fourth quartile; other
bbreviations as in Table 2.
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March 30, 2010:1362–9 Statin Treatment in Elderly Post-MI Patientsnd there is also evidence from the follow-up of randomized
rials of a long-term protective carryover effect of statins
16). Accordingly, there is a possibility that a more frequent
tatin pretreatment may have contributed to the increased
urvival observed in patients discharged on statin treatment.
owever, we did not observe an association between statin
reatment at hospital admission and increased follow-up
urvival in the present study (data not shown).
Despite a higher risk (3,8,9), older AMI patients are less
ikely to receive evidence-based medication (4). In accor-
ance, only 1 of 4 patients in the present study population
eceived statins at discharge. One factor that may contribute
o the lower use of evidence-based medicine in this age
roup is that controlled intervention trials mostly have
xcluded older patients. Only 1 randomized clinical statin
rial, PROSPER (12), was restricted to older patients (70 to
2 years). This study, which included both primary and
econdary prevention cohorts, showed a 15% reduction in
ardiovascular events in the statin group but no effect on
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Figure 4 Adjusted Cumulative Risk of CVD Mortality Estimated
CVD  cardiovascular disease; other abbreviations and definitions as in Figure 2.
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Figure 5 Adjusted Cumulative Risk of AMI Mortality Estimated
AMI  acute myocardial infarction; abbreviations and definitions as in Figure 2.ll-cause mortality. The Heart Protection Study was not
esigned to specifically address the effect of statin treatment
n elderly patients, but a subgroup analysis of subjects
etween 70 and 80 years of age at baseline demonstrated an
R reduction equal to that for younger patients in the trial
17). Another factor that may have contributed to the lower
rescription of statins to elderly post-AMI patients is the
oncern for an increased risk of cancer. The potential of an
ncreased risk of cancer by cholesterol-lowering treatment
as widely debated in the pre-statin era. Although meta-
nalysis of long-term statin trials have revealed no support
or an increased cancer risk (18–20), the observation of a
igher incidence of cancer in the pravastatin group of the
ROSPER trial raised concerns that elderly patients could
e at particular risk. Reports of inverse associations between
lasma cholesterol and cancer rates in older persons (10)
ave also argued for precautions in treating elderly patients
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tudy limitations. There are several limitations of the
resent study that need to be considered. First, the inherent
imitations of a nonrandomized registry study should be
cknowledged. Despite appropriate statistical adjustments,
nknown confounders may have affected the results. Al-
hough our analyses included controlling for the prevalence
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hether the reduced cardiovascular mortality observed
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ted with lower cardiovascular mortality risk also when all
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gainst this possibility. Moreover, a propensity score was
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eing prescribed statin treatment. Another limiting factor
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